Boston-based Verastem has raised $32 million through a Series B venture capital financing. The investment was led by Advanced Technology Ventures and Astellas Venture Management.
Existing investors Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital also participated. The biopharmaceutical company intends to use the proceeds to support ongoing research and development.
Click here for the release from Business Wire.